ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy

In Gyu Hwang, Myung Ju Ahn, Byeong-Bae Park, Yong Chan Ahn, Joungho Han, Seungkoo Lee, Jhingook Kim, Young Mog Shim, Jin Seok Ahn, Keunchil Park

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

BACKGROUND. Excision repair cross-complementation Group 1 (ERCC1) overexpression is associated with resistance to cisplatin-based chemotherapy in patients with nonsmall-cell lung cancer (NSCLC). A preliminary study also suggested that ERCC1 expression is associated with radioresistance in lung cancer cells. The aim of this study was to evaluate the clinical implications of ERCC1 expression in stage IIIA N2-positive NSCLC patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery. METHODS. Sixty-eight patients with mediastinoscopy-proven N2-positive NSCLC were enrolled between August 1997 and September 2003. ERCC1 expression was assessed by immunohistochemistry from pretreatment mediastinoscopic biopsy specimens. RESULTS. ERCC1 expression was positive in 31 of 68 specimens (46%). Among 14 patients who obtained pathologic complete response, 6 were positive for ERCC1 expression and 8 were negative (P = .818). On univariate analysis, with median follow-up of 61.8 months (range, 34.3-108.8 months), progression-free survival was 15.9 months for ERCC1 -positive and 29.5 months for ERCC1-negative patients (P = .062), and there was a statistically significant difference in overall survival between ERCC1-negative tumors and ERCC1-positive tumors (89.2 vs 26.0 months, P = .014). On multivariate analysis, ERCC1 negativity (P = .041) and achieving mediastinal nodal clearance (downstage to pathological N0 or N1) after neoadjuvant CCRT followed by surgery (P = .005) were significant independent prognostic factors for the prolongation of survival. CONCLUSIONS. These results suggest that N2-positive NSCLC patients with ERCC1 negative tumors show a survival benefit from neoadjuvant CCRT with a platinum-containing regimen. Cancer Society.

Original languageEnglish
Pages (from-to)1379-1386
Number of pages8
JournalCancer
Volume113
Issue number6
DOIs
StatePublished - 2008 Sep 15

Fingerprint

Chemoradiotherapy
Platinum
Non-Small Cell Lung Carcinoma
DNA Repair
Survival
Neoplasms
Mediastinoscopy
Cisplatin
Disease-Free Survival
Lung Neoplasms
Multivariate Analysis
Immunohistochemistry
Biopsy

Keywords

  • ERCC1
  • Neoaduvant concurrent chemoradiotherapy
  • Nonsmall-cell lung cancer
  • Prognosis

Cite this

Hwang, In Gyu ; Ahn, Myung Ju ; Park, Byeong-Bae ; Ahn, Yong Chan ; Han, Joungho ; Lee, Seungkoo ; Kim, Jhingook ; Shim, Young Mog ; Ahn, Jin Seok ; Park, Keunchil. / ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. In: Cancer. 2008 ; Vol. 113, No. 6. pp. 1379-1386.
@article{1732f81e0c5144e0ba801204919522da,
title = "ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy",
abstract = "BACKGROUND. Excision repair cross-complementation Group 1 (ERCC1) overexpression is associated with resistance to cisplatin-based chemotherapy in patients with nonsmall-cell lung cancer (NSCLC). A preliminary study also suggested that ERCC1 expression is associated with radioresistance in lung cancer cells. The aim of this study was to evaluate the clinical implications of ERCC1 expression in stage IIIA N2-positive NSCLC patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery. METHODS. Sixty-eight patients with mediastinoscopy-proven N2-positive NSCLC were enrolled between August 1997 and September 2003. ERCC1 expression was assessed by immunohistochemistry from pretreatment mediastinoscopic biopsy specimens. RESULTS. ERCC1 expression was positive in 31 of 68 specimens (46{\%}). Among 14 patients who obtained pathologic complete response, 6 were positive for ERCC1 expression and 8 were negative (P = .818). On univariate analysis, with median follow-up of 61.8 months (range, 34.3-108.8 months), progression-free survival was 15.9 months for ERCC1 -positive and 29.5 months for ERCC1-negative patients (P = .062), and there was a statistically significant difference in overall survival between ERCC1-negative tumors and ERCC1-positive tumors (89.2 vs 26.0 months, P = .014). On multivariate analysis, ERCC1 negativity (P = .041) and achieving mediastinal nodal clearance (downstage to pathological N0 or N1) after neoadjuvant CCRT followed by surgery (P = .005) were significant independent prognostic factors for the prolongation of survival. CONCLUSIONS. These results suggest that N2-positive NSCLC patients with ERCC1 negative tumors show a survival benefit from neoadjuvant CCRT with a platinum-containing regimen. Cancer Society.",
keywords = "ERCC1, Neoaduvant concurrent chemoradiotherapy, Nonsmall-cell lung cancer, Prognosis",
author = "Hwang, {In Gyu} and Ahn, {Myung Ju} and Byeong-Bae Park and Ahn, {Yong Chan} and Joungho Han and Seungkoo Lee and Jhingook Kim and Shim, {Young Mog} and Ahn, {Jin Seok} and Keunchil Park",
year = "2008",
month = "9",
day = "15",
doi = "10.1002/cncr.23693",
language = "English",
volume = "113",
pages = "1379--1386",
journal = "Cancer",
issn = "0008-543X",
number = "6",

}

ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. / Hwang, In Gyu; Ahn, Myung Ju; Park, Byeong-Bae; Ahn, Yong Chan; Han, Joungho; Lee, Seungkoo; Kim, Jhingook; Shim, Young Mog; Ahn, Jin Seok; Park, Keunchil.

In: Cancer, Vol. 113, No. 6, 15.09.2008, p. 1379-1386.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy

AU - Hwang, In Gyu

AU - Ahn, Myung Ju

AU - Park, Byeong-Bae

AU - Ahn, Yong Chan

AU - Han, Joungho

AU - Lee, Seungkoo

AU - Kim, Jhingook

AU - Shim, Young Mog

AU - Ahn, Jin Seok

AU - Park, Keunchil

PY - 2008/9/15

Y1 - 2008/9/15

N2 - BACKGROUND. Excision repair cross-complementation Group 1 (ERCC1) overexpression is associated with resistance to cisplatin-based chemotherapy in patients with nonsmall-cell lung cancer (NSCLC). A preliminary study also suggested that ERCC1 expression is associated with radioresistance in lung cancer cells. The aim of this study was to evaluate the clinical implications of ERCC1 expression in stage IIIA N2-positive NSCLC patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery. METHODS. Sixty-eight patients with mediastinoscopy-proven N2-positive NSCLC were enrolled between August 1997 and September 2003. ERCC1 expression was assessed by immunohistochemistry from pretreatment mediastinoscopic biopsy specimens. RESULTS. ERCC1 expression was positive in 31 of 68 specimens (46%). Among 14 patients who obtained pathologic complete response, 6 were positive for ERCC1 expression and 8 were negative (P = .818). On univariate analysis, with median follow-up of 61.8 months (range, 34.3-108.8 months), progression-free survival was 15.9 months for ERCC1 -positive and 29.5 months for ERCC1-negative patients (P = .062), and there was a statistically significant difference in overall survival between ERCC1-negative tumors and ERCC1-positive tumors (89.2 vs 26.0 months, P = .014). On multivariate analysis, ERCC1 negativity (P = .041) and achieving mediastinal nodal clearance (downstage to pathological N0 or N1) after neoadjuvant CCRT followed by surgery (P = .005) were significant independent prognostic factors for the prolongation of survival. CONCLUSIONS. These results suggest that N2-positive NSCLC patients with ERCC1 negative tumors show a survival benefit from neoadjuvant CCRT with a platinum-containing regimen. Cancer Society.

AB - BACKGROUND. Excision repair cross-complementation Group 1 (ERCC1) overexpression is associated with resistance to cisplatin-based chemotherapy in patients with nonsmall-cell lung cancer (NSCLC). A preliminary study also suggested that ERCC1 expression is associated with radioresistance in lung cancer cells. The aim of this study was to evaluate the clinical implications of ERCC1 expression in stage IIIA N2-positive NSCLC patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery. METHODS. Sixty-eight patients with mediastinoscopy-proven N2-positive NSCLC were enrolled between August 1997 and September 2003. ERCC1 expression was assessed by immunohistochemistry from pretreatment mediastinoscopic biopsy specimens. RESULTS. ERCC1 expression was positive in 31 of 68 specimens (46%). Among 14 patients who obtained pathologic complete response, 6 were positive for ERCC1 expression and 8 were negative (P = .818). On univariate analysis, with median follow-up of 61.8 months (range, 34.3-108.8 months), progression-free survival was 15.9 months for ERCC1 -positive and 29.5 months for ERCC1-negative patients (P = .062), and there was a statistically significant difference in overall survival between ERCC1-negative tumors and ERCC1-positive tumors (89.2 vs 26.0 months, P = .014). On multivariate analysis, ERCC1 negativity (P = .041) and achieving mediastinal nodal clearance (downstage to pathological N0 or N1) after neoadjuvant CCRT followed by surgery (P = .005) were significant independent prognostic factors for the prolongation of survival. CONCLUSIONS. These results suggest that N2-positive NSCLC patients with ERCC1 negative tumors show a survival benefit from neoadjuvant CCRT with a platinum-containing regimen. Cancer Society.

KW - ERCC1

KW - Neoaduvant concurrent chemoradiotherapy

KW - Nonsmall-cell lung cancer

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=53149098596&partnerID=8YFLogxK

U2 - 10.1002/cncr.23693

DO - 10.1002/cncr.23693

M3 - Article

C2 - 18623378

AN - SCOPUS:53149098596

VL - 113

SP - 1379

EP - 1386

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -